Toward a noncytotoxic glioblastoma therapy: Blocking MCP-1 with the MTZ regimen

OncoTargets and Therapy

Volumn 9, Issue , 2016, Pages 2535-2545

  Salacz, Michael E ^a   Kast, Richard E ^b   Saki, Najmaldin ^c   Brüning, Ansgar ^d   Karpel Massler, Georg ^e   Halatsch, Marc Eric ^e  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b IIAIGC Study Center   (United States)

^c AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

Cognition sparing; High grade glioma; Immunosuppression; Macrophage; Microglia; Monocyte

Indexed keywords

BEVACIZUMAB; MINOCYCLINE; MONOCYTE CHEMOTACTIC PROTEIN 1; TELMISARTAN; TEMOZOLOMIDE; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BLOOD BRAIN BARRIER; BONE DISEASE; BREAST CANCER; CANCER INHIBITION; CANCER PROGNOSIS; CELL INFILTRATION; DRUG COST; DRUG EFFICACY; DRUG PENETRATION; DRUG REPOSITIONING; DRUG SAFETY; DRUG TOLERABILITY; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; GLIOMA; HUMAN; HYPERCALCEMIA; HYPERPIGMENTATION; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LUPUS VULGARIS; MACROPHAGE ACTIVATION; MONOCYTE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; REVIEW; SERUM SICKNESS; SURVIVAL TIME; TREATMENT DURATION; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT;

EID: 84982236974     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S100407     Document Type: Review

References (130)

1. Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP, Vikas P. The Repurposing Drugs in Oncology (ReDO) Project. Ecancermedicalscience. 2014;8:442. doi:10.3332/ecancer.2014.442.
2. Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. Repurposing drugs in your medicine cabinet: untapped opportunities for cancer therapy? Future Oncol. 2015;11(2):181-184. doi:10.2217/fon.14.244.
3. Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP. Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent. Ecancermedicalscience. 2015;9:521. doi:10.3332/ecancer.2015.521.
4. Kast RE, Karpel-Massler G, Halatsch ME. CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget. 2014;5(18):8052-8082.
5. Safa AR, Saadatzadeh MR, Cohen-Gadol AA, Pollok KE, Bijangi-Vishehsaraei K. Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs. Genes Dis. 2015;2(2):152-163.
6. Tang C, Guo J, Chen H, et al. Gene mutation profiling of primary glioblastoma through multiple tumor biopsy guided by (1)H-magnetic resonance spectroscopy. Int J Clin Exp Pathol. 2015;8(5):5327-5335.
7. Lemée JM, Clavreul A, Menei P. Intratumoral heterogeneity in glioblastoma: don’t forget the peritumoral brain zone. Neuro Oncol. 2015;17(10):1322-1332.
8. Kast RE. Agomelatine or ramelteon as treatment adjuncts in glioblastoma and other M1-or M2-expressing cancers. Contemp Oncol (Pozn). 2015;19(2):157-162. doi:10.5114/wo.2015.51421.
9. Harry GJ. Microglia during development and aging. Pharmacol Ther. 2013;139(3):313-326. doi:10.1016/j.pharmthera.2013.04.013.
10. Klatzo I. A study of glia by the Golgi method. Lab Invest. 1952;1(3):345-350.
11. Ginhoux F, Prinz M. Origin of microglia: current concepts and past controversies. Cold Spring Harb Perspect Biol. 2015;7(8):a020537. doi:10.1101/cshperspect.a020537.
12. Lisi L, Stigliano E, Lauriola L, Navarra P, Dello Russo C. Proinflammatory-activated glioma cells induce a switch in microglial polarization and activation status, from a predominant M2b phenotype to a mixture of M1 and M2a/B polarized cells. ASN Neuro. 2014;6(3):171-183. doi:10.1042/AN20130045.
13. Markovic DS, Glass R, Synowitz M, Rooijen NV, Kettenmann H. Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2. J Neuropathol Exp Neurol. 2005;64(9):754-762.
14. Hattermann K, Sebens S, Helm O, et al. Chemokine expression profile of freshly isolated human glioblastoma-associated macrophages/microglia. Oncol Rep. 2014;32(1):270-276. doi:10.3892/or.2014.3214.
15. Glass R, Synowitz M. CNS macrophages and peripheral myeloid cells in brain tumours. Acta Neuropathol. 2014;128(3):347-362. doi:10.1007/s00401-014-1274-2.
16. Vinnakota K, Hu F, Ku MC, et al. Toll-like receptor 2 mediates microglia/brain macrophage MT1-MMP expression and glioma expansion. Neuro Oncol. 2013;15(11):1457-1468. doi:10.1093/neuonc/not115.
17. Zhou W, Bao S. Reciprocal supportive interplay between glioblastoma and tumor-associated macrophages. Cancers (Basel). 2014;6(2):723-740. doi:10.3390/cancers6020723.
18. Coniglio SJ, Eugenin E, Dobrenis K, et al. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol Med. 2012;18:519-527. doi:10.2119/molmed.2011.00217.
19. Hewedi IH, Radwan NA, Shash LS, Elserry TH. Perspectives on the immunologic microenvironment of astrocytomas. Cancer Manag Res. 2013;5:293-299. doi:10.2147/CMAR.S48942.
20. Couldwell WT, Fraser G, De Vellis G, Antel JP, Villemure JG, Yong VW. Malignant glioma-derived soluble factors regulate proliferation of normal adult human astrocytes. J Neuropathol Exp Neurol. 1992;51(5):506-513.
21. Atai NA, Bansal M, Lo C, et al. Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology. 2011;132(1):39-48. doi:10.1111/j.1365-2567.2010.03335.x.
22. da Fonseca AC, Badie B. Microglia and macrophages in malignant gliomas: recent discoveries and implications for promising therapies. Clin Dev Immunol. 2013;2013:264124. doi:10.1155/2013/264124.
23. Feng X, Szulzewsky F, Yerevanian A, et al. Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis. Oncotarget. 2015;6(17):15077-15094.
24. Szulzewsky F, Pelz A, Feng X, et al. Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1. PLoS One. 2015;10(2):e0116644. doi:10.1371/journal.pone.0116644.
25. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia. 2011;59(8):1169-1180. doi:10.1002/glia.21136.
26. Alves TR, Lima FR, Kahn SA, et al. Glioblastoma cells: a heterogeneous and fatal tumor interacting with the parenchyma. Life Sci. 2011;89(15-16):532-539. doi:10.1016/j.lfs.2011.04.022.
27. Zhou W, Ke SQ, Huang Z, et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol. 2015;17(2):170-182. doi:10.1038/ncb3090.
28. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008;216(1):15-24. doi:10.1002/path.2370.
29. Hu F, Ku MC, Markovic D, et al. Glioma-associated microglial MMP9 expression is upregulated by TLR2 signaling and sensitive to minocycline. Int J Cancer. 2014;135(11):2569-2578. doi:10.1002/ijc.28908.
30. Kast RE, Scheuerle A, Wirtz CR, Karpel-Massler G, Halatsch ME. The rationale of targeting neutrophils with dapsone during glioblastoma treatment. Anticancer Agents Med Chem. 2011;11(8):756-761.
31. Kast RE, Lefranc F, Karpel-Massler G, Halatsch ME. Why dapsone stops seizures and may stop neutrophils’ delivery of VEGF to glioblastoma. Br J Neurosurg. 2012;26(6):813-817. doi:10.3109/02688697.2012.674577.
32. Liang J, Piao Y, Holmes L, et al. Neutrophils promote the malignant glioma phenotype through S100A4. Clin Cancer Res. 2014;20(1):187-198. doi:10.1158/1078-0432.CCR-13-1279.
33. Fossati G, Ricevuti G, Edwards SW, Walker C, Dalton A, Rossi ML. Neutrophil infiltration into human gliomas. Acta Neuropathol. 1999;98(4):349-354.
34. Sippel TR, White J, Nag K, et al. Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. Clin Cancer Res. 2011;17(22):6992-7002. doi:10.1158/1078-0432.CCR-11-1107.
35. Iwatsuki K, Kumara E, Yoshimine T, Nakagawa H, Sato M, Hayakawa T. Elastase expression by infiltrating neutrophils in gliomas. Neurol Res. 2000;22(5):465-468.
36. Lapa C, Linsenmann T, Lückerath K, et al. Tumor-associated macrophages in glioblastoma multiforme-a suitable target for somatostatin receptor-based imaging and therapy? PLoS One. 2015;10(3):e0122269. doi:10.1371/journal.pone.0122269.
37. Leung SY, Wong MP, Chung LP, Chan AS, Yuen ST. Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol. 1997;93(5):518-527.
38. Klein R, Roggendorf W. Increased microglia proliferation separates pilocytic astrocytomas from diffuse astrocytomas: a double labeling study. Acta Neuropathol. 2001;101(3):245-248.
39. Squadrito ML, De Palma M. A niche role for periostin and macrophages in glioblastoma. Nat Cell Biol. 2015;17(2):107-109. doi:10.1038/ncb3095.
40. Sielska M, Przanowski P, Wylot B, et al. Distinct roles of CSF family cytokines in macrophage infiltration and activation in glioma progression and injury response. J Pathol. 2013;230(3):310-321. doi:10.1002/path.4192.
41. Rodero M, Marie Y, Coudert M, et al. Polymorphism in the microglial cell-mobilizing CX3CR1 gene is associated with survival in patients with glioblastoma. J Clin Oncol. 2008;26(36):5957-5964. doi:10.1200/JCO.2008.17.2833.
42. Prosniak M, Harshyne LA, Andrews DW, et al. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clin Cancer Res. 2013;19(14):3776-3786. doi:10.1158/1078-0432.CCR-12-1940.
43. Wu A, Wei J, Kong LY, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010;12(11):1113-1125. doi:10.1093/neuonc/noq082.
44. de Vrij J, Maas SL, Kwappenberg KM, et al. Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells. Int J Cancer. 2015;137(7):1630-1642. doi:10.1002/ijc.29521.
45. He L, Marneros AG. Doxycycline inhibits polarization of macrophages to the proangiogenic M2-type and subsequent neovascularization. J Biol Chem. 2014;289(12):8019-8028. doi:10.1074/jbc.M113.535765.
46. Getts DR, Terry RL, Getts MT, et al. Ly6c+ “inflammatory monocytes” are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis. J Exp Med. 2008;205(10):2319-2337. doi:10.1084/jem.20080421.
47. Chae M, Peterson TE, Balgeman A, et al. Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model. Neuro Oncol. 2015;17(7):978-991. doi:10.1093/neuonc/nou343.
48. Gielen PR, Schulte BM, Kers-Rebel ED, et al. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue. J Neuropathol Exp Neurol. 2015;74(5):390-400.
49. Rodrigues JC, Gonzalez GC, Zhang L, et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol. 2010;12(4):351-365. doi:10.1093/neuonc/nop023.
50. Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res. 2013;19(12):3165-3175. doi:10.1158/1078-0432.CCR-12-3314.
51. Thorne AH, Meisen WH, Russell L, et al. Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance. Mol Ther. 2014;22(9):1678-1687. doi:10.1038/mt.2014.101.
52. Boukhari A, Alhosin M, Bronner C, et al. CD47 activation-induced UHRF1 over-expression is associated with silencing of tumor suppressor gene p16INK4A in glioblastoma cells. Anticancer Res. 2015;35(1):149-157.
53. Pyonteck SM, Akkari L, Schuhmacher AJ, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264-1272. doi:10.1038/nm.3337.
54. Kohanbash G, McKaveney K, Sakaki M, et al. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-alpha. Cancer Res. 2013;73(21):6413-6423. doi:10.1158/0008-5472.CAN-12-4124.
55. Albulescu R, Codrici E, Popescu ID, et al. Cytokine patterns in brain tumour progression. Mediators Inflamm. 2013;2013:979748. doi:10.1155/2013/979748.
56. Revoltella RP, Menicagli M, Campani D. Granulocyte-macrophage colony-stimulating factor as an autocrine survival-growth factor in human gliomas. Cytokine. 2012;57(3):347-359. doi:10.1016/j.cyto.2011.11.016.
57. Curran CS, Evans MD, Bertics PJ. GM-CSF production by glioblastoma cells has a functional role in eosinophil survival, activation, and growth factor production for enhanced tumor cell proliferation. J Immunol. 2011;187(3):1254-1263. doi:10.4049/jimmunol.1001965.
58. Mueller MM, Herold-Mende CC, Riede D, Lange M, Steiner HH, Fusenig NE. Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. Am J Pathol. 1999;155(5):1557-1567.
59. Vasco C, Canazza A, Rizzo A, et al. Circulating T regulatory cells migration and phenotype in glioblastoma patients: an in vitro study. J Neurooncol. 2013;115(3):353-363. doi:10.1007/s11060-013-1236-x.
60. Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother. 2008;57(1):123-131.
61. Lin Y, Zhang G, Zhang J, et al. A panel of four cytokines predicts the prognosis of patients with malignant gliomas. J Neurooncol. 2013;114(2):199-208. doi:10.1007/s11060-013-1171-x.
62. Liang Y, Bollen AW, Gupta N. CC chemokine receptor-2A is frequently overexpressed in glioblastoma. J Neurooncol. 2008;86(2):153-163.
63. Lindemann C, Marschall V, Weigert A, Klingebiel T, Fulda S. Smac mimetic-induced upregulation of CCL2/MCP-1 triggers migration and invasion of glioblastoma cells and influences the tumor microenvironment in a paracrine manner. Neoplasia. 2015;17(6):481-489. doi:10.1016/j.neo.2015.05.002.
64. Kuratsu J, Yoshizato K, Yoshimura T, Leonard EJ, Takeshima H, Ushio Y. Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma. J Natl Cancer Inst. 1993;85(22):1836-1839.
65. Desbaillets I, Tada M, de Tribolet N, Diserens AC, Hamou MF, Van Meir EG. Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro. Int J Cancer. 1994;58(2):240-247.
66. Wurdinger T, Deumelandt K, van der Vliet HJ, Wesseling P, de Gruijl TD. Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: how to break a vicious cycle. Biochim Biophys Acta. 2014;1846(2):560-575. doi:10.1016/j.bbcan.2014.10.003.
67. Lu-Emerson C, Snuderl M, Kirkpatrick ND, et al. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol. 2013;15(8):1079-1087. doi:10.1093/neuonc/not082.
68. Elewa HF, Hilali H, Hess DC, Machado LS, Fagan SC. Minocycline for short-term neuroprotection. Pharmacotherapy. 2006;26(4):515-521.
69. Saivin S, Hovin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988;15:355-366.
70. Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res. 2009;196(2):168-179. doi:10.1016/j.bbr.2008.09.040.
71. Ochsendorf F. Minocycline in acne vulgaris: benefits and risks. Am J Clin Dermatol. 2010;11(5):327-341. doi:10.2165/11319280-000000000-00000.
72. Garrido-Mesa N, Zarzuelo A, Galvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169(2):337-352. doi:10.1111/bph.12139.
73. Mitchell RM, Lee SY, Randazzo WT, Simmons Z, Connor JR. Influence of HFE variants and cellular iron on monocyte chemoattractant protein-1. J Neuroinflammation. 2009;6:6. doi:10.1186/1742-2094-6-6.
74. Tai K, Iwasaki H, Ikegaya S, Ueda T. Minocycline modulates cytokine and chemokine production in lipopolysaccharide-stimulated THP-1 monocytic cells by inhibiting IkB kinase alpha/beta phosphorylation. Transl Res. 2013;161(2):99-109. doi:10.1016/j.trsl.2012.10.001.
75. Dutta K, Kumawat KL, Nazmi A, Mishra MK, Basu A. Minocycline differentially modulates viral infection and persistence in an experimental model of Japanese encephalitis. J Neuroimmune Pharmacol. 2010;5(4):553-565. doi:10.1007/s11481-010-9233-8.
76. Zink MC, Uhrlaub J, DeWitt J, et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA. 2005;293(16):2003-2011.
77. Quick ED, Leser JS, Clarke P, Tyler KL. Activation of intrinsic immune responses and microglial phagocytosis in an ex vivo spinal cord slice culture model of West Nile virus infection. J Virol. 2014;88(22):13005-13014. doi:10.1128/JVI.01994-14.
78. Abcouwer SF, Lin CM, Shanmugam S, Muthusamy A, Barber AJ, Antonetti DA. Minocycline prevents retinal inflammation and vascular permeability following ischemia-reperfusion injury. J Neuroinflammation. 2013;10:149. doi:10.1186/1742-2094-10-149.
79. Teicher BA, Dupuis NP, Emi Y, Ikebe M, Kakeji Y, Menon K. Increased efficacy of chemo-and radio-therapy by a hemoglobin solution in the 9L gliosarcoma. In Vivo. 1995;9(1):11-18.
80. Weingart JD, Sipos EP, Brem H. The role of minocycline in the treatment of intracranial 9L glioma. J Neurosurg. 1995;82(4):635-640.
81. Frazier JL, Wang PP, Case D, et al. Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma. J Neurooncol. 2003;64(3):203-209.
82. Bow H, Hwang LS, Schildhaus N, et al. Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma. J Neurosurg. 2014;120(3):662-669. doi:10.3171/2013.11.JNS13556.
83. Liu WT, Lin CH, Hsiao M, Gean PW. Minocycline inhibits the growth of glioma by inducing autophagy. Autophagy. 2011;7(2):166-175.
84. Hour MJ, Liu WT, Lu IC, Kuo SC, Gean PW. Aggravated DNA damage as a basis for enhanced glioma cell killing by MJ-66 in combination with minocycline. Am J Cancer Res. 2014;4(5):474-483.
85. Markovic DS, Vinnakota K, van Rooijen N, et al. Minocycline reduces glioma expansion and invasion by attenuating microglial MT1-MMP expression. Brain Behav Immun. 2011;25(4):624-628. doi:10.1016/j.bbi.2011.01.015.
86. Eisen D, Hakim MD. Minocycline-induced pigmentation. Incidence, prevention and management. Drug Saf. 1998;18(6):431-440.
87. Eichenfield AH. Minocycline and autoimmunity. Curr Opin Pediatr. 1999;11(5):447-456.
88. Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an overview. Semin Arthritis Rheum. 1999;28(6):392-397.
89. Bakheit AH, Abd-Elgalil AA, Mustafa B, Haque A, Wani TA. Telmisartan. Profiles Drug Subst Excip Relat Methodol. 2015;40:371-429. doi:10.1016/bs.podrm.2015.01.003.
90. Zhang J, Wong MG, Wong M, et al. A cationic-independent mannose 6-phosphate receptor inhibitor (PXS64) ameliorates kidney fibrosis by inhibiting activation of transforming growth factor-beta. PLoS One. 2015;10(2):e0116888. doi:10.1371/journal.pone.0116888.
91. Gangadharan Komala M, Gross S, Mudaliar H, et al. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice. PLoS One. 2014;9(11):e108994. doi:10.1371/journal.pone.0108994.
92. Kurata T, Lukic V, Kozuki M, et al. Telmisartan reduces progressive accumulation of cellular amyloid beta and phosphorylated tau with inflammatory responses in aged spontaneously hypertensive stroke resistant rat. J Stroke Cerebrovasc Dis. 2014;23(10):2580-2590. doi:10.1016/j.jstrokecerebrovasdis.2014.05.023.
93. Kono S, Kurata T, Sato K, et al. Neurovascular protection by telmisartan via reducing neuroinflammation in stroke-resistant spontaneously hypertensive rat brain after ischemic stroke. J Stroke Cerebrovasc Dis. 2015;24(3):537-547. doi:10.1016/j.jstrokecerebrovasdis.2014.09.037.
94. Xu S, Song H, Huang M, Wang K, Xu C, Xie L. Telmisartan inhibits the proinflammatory effects of homocysteine on human endothelial cells through activation of the peroxisome proliferator-activated receptor-gamma pathway. Int J Mol Med. 2014;34(3):828-834. doi:10.3892/ijmm.2014.1834.
95. Kudo H, Yata Y, Takahara T, et al. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver Int. 2009;29(7):988-996. doi:10.1111/j.1478-3231.2009.02006.x.
96. Dai Q, Xu M, Yao M, Sun B. Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats. Br J Pharmacol. 2007;152(7):1042-1048.
97. Liu Z, Zhao Y, Wei F, et al. Treatment with telmisartan/rosuvastatin combination has a beneficial synergistic effect on ameliorating Th17/Treg functional imbalance in hypertensive patients with carotid atherosclerosis. Atherosclerosis. 2014;233(1):291-299. doi:10.1016/j.atherosclerosis.2013.12.004.
98. Klinghammer L, Urschel K, Cicha I, et al. Impact of telmisartan on the inflammatory state in patients with coronary atherosclerosis-influence on IP-10, TNF-alpha and MCP-1. Cytokine. 2013;62(2):290-296. doi:10.1016/j.cyto.2013.02.001.
99. Mohamed MM, El-Ghonaimy EA, Nouh MA, Schneider RJ, Sloane BF, El-Shinawi M. Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties. Int J Biochem Cell Biol. 2014;46:138-147. doi:10.1016/j.biocel.2013.11.015.
100. Guo Z, Zhang R, Li J, Xu G. Effect of telmisartan on the expression of adiponectin receptors and nicotinamide adenine dinucleotide phosphate oxidase in the heart and aorta in type 2 diabetic rats. Cardiovasc Diabetol. 2012;11:94. doi:10.1186/1475-2840-11-94.
101. Sonoki K, Iwase M, Ohdo S, et al. Telmisartan and N-acetylcysteine suppress group V secretory phospholipase A2 expression in TNF-alpha stimulated human endothelial cells and reduce associated atherogenicity. J Cardiovasc Pharmacol. 2012;60(4):367-374. doi:10.1097/FJC.0b013e3182646ccc.
102. Pang T, Benicky J, Wang J, Orecna M, Sanchez-Lemus E, Saavedra JM. Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-gamma activation in human monocytes. J Hypertens. 2012;30(1):87-96. doi:10.1097/HJH.0b013e32834dde5f.
103. Matsumura T, Kinoshita H, Ishii N, et al. Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-gamma in macrophages. Arterioscler Thromb Vasc Biol. 2011;31(6):1268-1275. doi:10.1161/ATVBAHA.110.222067.
104. Marketou ME, Kontaraki JE, Tsakountakis NA, et al. Differential effect of telmisartan and amlodipine on monocyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension. Am J Cardiol. 2011;107(1):59-63. doi:10.1016/j.amjcard. 2010.08.048.
105. Pan Q, Yang XH, Cheng YX. Angiotensin II stimulates MCP-1 production in rat glomerular endothelial cells via NAD(P)H oxidase-dependent nuclear factor-kappa B signaling. Braz J Med Biol Res. 2009;42(6):531-536.
106. Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist. 2005;10(1):52-62.
107. Perry CM, Figgitt DP. Zoledronic acid: a review of its use in patients with advanced cancer. Drugs. 2004;64(11):1197-1211.
108. Li EC, Davis LE. Zoledronic acid: a new parenteral bisphosphonate. Clin Ther. 2003;25(11):2669-2708.
109. Kaiser T, Teufel I, Geiger K, et al. Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells. Breast Cancer Res Treat. 2013;140(1):35-48. doi:10.1007/s10549-013-2613-z.
110. Ohba T, Cole HA, Cates JM, et al. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL. J Bone Miner Res. 2014;29(6):1431-1445. doi:10.1002/jbmr.2182.
111. He M, Fan W, Zhang X. Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis. J Hematol Oncol. 2013;6(1):80. doi:10.1186/1756-8722-6-80.
112. Rietkotter E, Menck K, Bleckmann A, et al. Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion. Oncotarget. 2013;4(9):1449-1460.
113. Hiroshima Y, Maawy A, Hassanein MK, et al. The tumor-educated-macrophage increase of malignancy of human pancreatic cancer is prevented by zoledronic acid. PLoS One. 2014;9(8):e103382. doi:10.1371/journal.pone.0103382.
114. Rogers TL, Holen I. Tumour macrophages as potential targets of bisphosphonates. J Transl Med. 2011;9:177. doi:10.1186/1479-5876-9-177.
115. Cynis H, Kehlen A, Haegele M, et al. Inhibition of glutaminyl cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice. Int J Exp Pathol. 2013;94(3):217-225. doi:10.1111/iep.12020.
116. Pae CU. The potential role of monocyte chemoattractant protein-1 for major depressive disorder. Psychiatry Investig. 2014;11(3):217-222. doi:10.4306/pi.2014.11.3.217.
117. Nowak M, Strzelczyk A, Reif PS, et al. Minocycline as potent anticonvulsant in a patient with astrocytoma and drug resistant epilepsy. Seizure. 2012;21(3):227-228. doi:10.1016/j.seizure.2011.12.009.
118. Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71(2):138-149. doi:10.4088/JCP.08m04666yel.
119. Liu F, Guo X, Wu R, et al. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res. 2014;153(1-3):169-176. doi:10.1016/j.schres.2014.01.011.
120. Ghanizadeh A, Dehbozorgi S, Omrani Sigaroodi M, Rezaei Z. Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial. Recent Pat Inflamm Allergy Drug Discov. 2014;8(3):211-215.
121. Nasrallah H, Tandon R, Keshavan M. Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment. Epidemiol Psychiatr Sci. 2011;20(4):317-327.
122. Best MG, Sol N, Zijl S, Reijneveld JC, Wesseling P, Wurdinger T. Liquid biopsies in patients with diffuse glioma. Acta Neuropathol. 2015;129(6):849-865. doi:10.1007/s00401-015-1399-y.
123. Pukrop T, Dehghani F, Chuang HN, et al. Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way. Glia. 2010;58(12):1477-1489. doi:10.1002/glia.21022.
124. Hasegawa Y, Tang D, Takahashi N, Hayashizaki Y, Forrest AR. CCL2 enhances pluripotency of human induced pluripotent stem cells by activating hypoxia related genes. Sci Rep. 2014;4:5228. doi:10.1038/srep05228.
125. Jung HJ, Seo I, Jha BK, Suh SI, Suh MH, Baek WK. Minocycline inhibits angiogenesis in vitro through the translational suppression of HIF-1α. Arch Biochem Biophys. 2014;545:74-82. doi:10.1016/j.abb.2013.12.023.
126. Baer C, Squadrito ML, Iruela-Arispe ML, De Palma M. Reciprocal interactions between endothelial cells and macrophages in angiogenic vascular niches. Exp Cell Res. 2013;319(11):1626-1634. doi:10.1016/j.yexcr.2013.03.026.
127. Schruefer R, Lutze N, Schymeinsky J, Walzog B. Human neutrophils promote angiogenesis by a paracrine feedforward mechanism involving endothelial interleukin-8. Heart Circ Physiol. 2005;288:H1186-H1192.
128. Reddy K, Gaspar LE, Kavanagh BD, et al. Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide. J Neurooncol. 2013;114(1):111-116. doi:10.1007/s11060-013-1159-6.
129. Zhang L, Li K, Sun R, et al. Minocycline ameliorates cognitive impairment induced by whole-brain irradiation: an animal study. Radiat Oncol. 2014;9(1):281.
130. Januel E, Ursu R, Alkhafaji A, et al. Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma. Eur J Neurol. 2015;22(9):1304-1309. doi:10.1111/ene.12746.